Lung cancer is the leading cause of cancer-related deaths worldwide, often detected at advanced stages when treatment options are limited. Subtle immune and prometastatic molecular changes, however, can appear much earlier than tumors become visible on imaging.

The Lung Immunocarcinogenic Assay measures immune checkpoint activity, inflammatory signaling, and prometastatic biomarker patterns that contribute to lung cancer development and progression. This test supports earlier detection, precision therapy selection, and recurrence monitoring.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Lung Immunocarcinogenic Assay detects these disruptions at the molecular level so patients and clinicians can act early.

Early Risk Identification

Detects immune and molecular signals linked to lung cancer initiation before advanced progression.

Precision Oncology Tool

Provides biomarker insights for guiding immunotherapy and targeted therapy.

Monitoring Capability

Tracks molecular changes during treatment and remission for long-term care.

Complementary Evidence

Enhances imaging (CT, PET) and pathology with immune-molecular analysis.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Lung Immunocarcinogenic Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and lung cancer progression:

  • Immune checkpoint proteins (PD-L1, CTLA-4 pathways)

  • Tumor-promoting cytokines (IL-6, IL-8, TNF-α)

  • Angiogenesis factors (VEGF, FGF) supporting tumor vascularization

  • Tumor microenvironment and prometastatic signaling proteins

  • Oxidative stress and lung tissue damage biomarkers

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Patient registers securely through Persona Biomed’s portal.

02

Sample Collection

Standard blood draw at a certified lab or via mobile phlebotomy.

03

Laboratory Analysis

Assays evaluate immune and prometastatic activity specific to lung cancer.

04

Results Delivery

Physician-ready report delivered via the portal, with AI-powered patient summaries for clarity.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Current or former smokers at elevated risk of lung cancer.

  • Patients with suspicious nodules or abnormal lung imaging.

  • Individuals with family history or genetic predisposition to lung cancer.

  • Lung cancer patients in treatment or remission requiring biomarker monitoring.

Register Now for
Lung Immunocarcinogenic Assay

Register now for the Lung Immunocarcinogenic Assay to detect immune and molecular signals of lung cancer early and guide precision-driven care.

Register now